Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sera Prognostics ( (SERA) ) has provided an update.
On June 5, 2025, Sera Prognostics held its Annual Meeting of Stockholders, where 66.2% of eligible shares were represented. During the meeting, Jane F. Barlow, M.D. and Mansoor Raza Mirza, M.D. were elected to the Board of Directors for a three-year term, and Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Spark’s Take on SERA Stock
According to Spark, TipRanks’ AI Analyst, SERA is a Neutral.
Sera Prognostics faces significant challenges with profitability and revenue generation, reflected in the low financial performance and valuation scores. Technical analysis indicates bearish trends, adding to the overall risk profile. Positive developments in strategic initiatives and leadership changes provide some optimism but are outweighed by current financial difficulties.
To see Spark’s full report on SERA stock, click here.
More about Sera Prognostics
Sera Prognostics, Inc. operates in the healthcare industry, focusing on providing innovative diagnostic tests, particularly in the field of prenatal care.
Average Trading Volume: 154,128
Technical Sentiment Signal: Sell
Current Market Cap: $71.96M
See more insights into SERA stock on TipRanks’ Stock Analysis page.